Cancer gene therapy clinical trials: Lessons for the future

British Journal of Cancer

Volumn 85, Issue 10, 2001, Pages 1432-1436

  Galanis, E ^a   Russell, S ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer; Clinical trials; Gene therapy

Indexed keywords

CISPLATIN; DNA; FLUOROURACIL; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; LIPOSOME; ORNITHINE CARBAMOYLTRANSFERASE; PROTEIN P53;

ADENOVIRUS; CANCER; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; HUMAN; KINETICS; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; REVIEW; SAFETY; SIDE EFFECT; TREATMENT OUTCOME; VACCINIA VIRUS;

CLINICAL TRIALS; FORECASTING; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; VIRUSES;

EID: 0035900808     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.2129     Document Type: Review

References (45)

1. Gene therapy: A molecular approach to cancer treatment
2. Intratumoral injection of ONYX-015 for gastrointestinal tumors metastatic to the liver: A phase I trial
3. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
4. Gene therapy of human severe combined immunodeficiency (SCID)-XI disease
5. Adeovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma
6. Reovirus therapy of tumors with activated Ras pathway
7. Transfer of genes to humans: Early lessons and obstacles to success
8. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex
9. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience
10. ONYX-015, an E1B-55kD deleted adenovirus, potentiates radiation therapy in human malignant glioma xenografts
11. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric infection
12. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
13. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
14. Advances in the biological therapy and gene therapy of malignant disease
15. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
16. A phase I/II study of herpes simplex virus type 1 thymidine kinase 'suicide' gene therapy for recurrent glioblastoma
17. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
18. Clinical trials: Gene therapy death prompts review of adenovirus vector
19. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
20. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma
21. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial
22. Adenovirus mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
23. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
24. An intravenous phase I trial of a replication-competent virus, PV701, in the treatment of patients with advanced solid cancers
25. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
26. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
27. RAC tries to regain foothold
28. Hepatic artery infusion of Onyx-015, a selectively-replicating adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: A phase I/II trial
29. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
30. Gene therapy for cancer: What have we done and where are we going?
31. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
32. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells
33. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen HLA-B7B7
34. Replicating vectors for gene therapy of cancer: Risks, limitations and prospects
35. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study
36. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
37. Molecular and clinical activity of CN706, a PSA-selective oncolytic AD5 vector in a phase I trial in locally recurrent prostate cancer following radiation therapy
38. Adenoviruis-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
39. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen HLA-B7, in patients with metastatic melanoma
40. Ad5CMVp53 gene therapy for locally advanced prostate cancer where do we stand?
41. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
42. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC)
43. A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer
44. Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian cancer
45. Gene therapy of colorectal liver metastases using a recombinant adenovirus encoding WT p53 (SCH 58500) via hepatic artery infusion: A phase I study